• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears embolic microspheres from ABK Biomedical

September 12, 2022 By Sean Whooley

ABK Biomedical LogoABK Biomedical announced today that it received FDA 510(k) clearance for its Easi-Vue embolic microspheres for treating tumors.

Halifax, Nova Scotia-based ABK designed its microspheres for treating patients with arteriovenous malformations and hypervascular tumors.

Vascular embolization is an effective therapy for addressing symptoms of these conditions. ABK said in a news release that microsphere embolization reduces or eliminates the blood flow to the tumors.

Chief medical officer Dr. Aravind Arepally said that Easi-Vue microspheres offer a highly calibrated technology. They offer capabilities for visually targeted placement using conventional x-ray and fluoroscopy systems. He added that the technology, with a proprietary controlled-concentration delivery system, could potentially improve patient outcomes.

“We are excited to achieve FDA 510(k) clearance for this new technology that has the potential to advance the field of embolic therapies”, said Gary Donofrio, chief business officer of ABK Biomedical.  “This represents a major milestone for ABK as our team continues to execute our product development objectives.  We will partner with key physicians to understand the range of clinical utilization and optimization of Easi-Vue therapy.”

The company is also developing Eye90 microspheres for treating unresectable hepatic cellular carcinoma.

“ABK continues to significantly advance the development program of our Eye90 microspheres radio-embolic technology that’s being investigated for the treatment of patients with unresectable Hepatic Cellular Carcinoma (HCC),” Donofrio said. “Easi-Vue embolic microspheres share core technologies and design characteristics with Eye90 microspheres.  Both devices continue to add to our knowledge base regarding the clinical experience of the first glass radiopaque embolic microspheres therapy.”

Filed Under: Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Radiosurgery, Regulatory/Compliance Tagged With: ABK Biomedical

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS